13FPulse
中
BB

BBNX BETA BIONICS INC

2026Q2 · CUSIP 08659B102 · Sector: Healthcare & Biotech

Normal

Fund flows are within the usual range

Funds that own it
134
Institutions that reported holding it to the SEC
Net increase in holders
+4
Last quarter 130 → now 134
How unusual is that
Above average
Stronger buying than 52% of US stocks
What the filings say, in one paragraph

134 funds held BBNX at the end of 2026Q2, up 4 from the quarter before. Fund flows are within the usual range — nothing unusual. On the business itself, revenue over the last 12 months was $119M(YoY +52.5%), return on equity is -28.5%. BBNX has had 1 buying rushes in its history. It sits in the Healthcare & Biotech sector.

How many funds owned it, quarter by quarter

Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.

2025Q2: holders=116 2025Q3: holders=127 2025Q4: holders=156 2026Q1: holders=130 2026Q2: holders=134 -29 -14.5 +0 +14.5 +29 104134164 25Q225Q325Q426Q126Q2 Net change in holders (bars) Total funds holding (line)

What happened after each past buying rush 1 times in its history

Quarter of the rush How unusual then Price, next 3 months Price, next 6 months
2025Q4 Top 20% -24.9% —

These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.

Show all the numbers (large funds, value held, options…) ▾
Of them, large funds
68
Change in large funds
-2
Total value they hold
$753M
Funds buying for the first time
32
Funds that sold out entirely
28
Price change that quarter
+106.5%
Funds holding puts (bearish)
0
Funds holding calls (bullish)
3

These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.

8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.

Fundamentals

PE (TTM)
—
EPS (TTM)
$-1.51
EPS YoY
—
Revenue (TTM)
$0.1B
Revenue YoY
+52.5%
Net margin
-61.3%
ROE
-28.5%
Debt ratio
12.3%
FCF (TTM)
-$61M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS
2025-03-31: EPS -0.93 2025-06-30: EPS -0.39 2025-09-30: EPS -0.33 2025-12-31: EPS -0.16 2026-03-31: EPS -0.49 2026-06-30: EPS -0.53 0M 16M 32M $M -1.02 -0.51 0.00 20242025202606/26 Revenue EPS

Quarterly figures, revenue up to 10 years back; EPS split-adjusted, early quarters hidden when not calibrable

Quarterly free cash flow
-25M-13M0K 202420252026
Latest quarter $-25M (2026-03-31)

FCF = operating cash flow − capex, computed from SEC XBRL; banks/insurers have no standard cash-flow structure and are hidden

As of 2026-06-30 · SEC filings (XBRL)

Email me the next update

2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.